In summary, our results identify overexpression of HOXA9, HOXA10, and MYB as critical drivers of CML progression, and suggest MYB as a key therapeutic target for inhibiting the self-renewal of leukemia-initiating cells in CML myeloid blast crisis patients. This evidence concerns the gene HOXA9 and chronic myelogenous leukemia, BCR-ABL1 positive.